Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Gabrene
2. Sl 76002
1. 62666-20-0
2. Halogabide
3. Gabren
4. Gabrene
5. Progabidum [inn-latin]
6. Progabida [inn-spanish]
7. 4-(((4-chlorophenyl)(5-fluoro-2-hydroxyphenyl)methylene)amino)butanamide
8. Sl 76002
9. Progabide, (z)-
10. Sl-76002
11. Sl 76 002
12. 112e50torv
13. 4-[[(e)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide
14. Butanamide, 4-(((4-chlorophenyl)(5-fluoro-2-hydroxyphenyl)methylene)amino)-
15. 38c836j57z
16. Progabida
17. Progabidum
18. Progabide [usan:ban:inn]
19. Progabide [usan:inn:ban]
20. Progabide (usan/inn)
21. Sl 76-002
22. Butanamide, 4-(((4-chlorophenyl)(5-fluoro-2-hydroxyphenyl)methylene)amino)-, (z)-
23. Butanamide, 4-[[(4-chlorophenyl)(5-fluoro-2-hydroxyphenyl)methylene]amino]-, (e)-
24. 104880-78-6
25. 90656-51-2
26. Gabren (tn)
27. Einecs 263-679-4
28. Brn 2339306
29. Unii-38c836j57z
30. 4-((alpha-(p-chlorophenyl)-5-fluorosalicylidene)amino)butyramide
31. 4-(alpha-(p-chlorophenyl)-5-fluoro-2-hydroxybenzylideneamino)butyramide
32. 4-[[(z)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide
33. Progabide [inn]
34. Progabide [mi]
35. Progabide [usan]
36. Progabide [mart.]
37. Butyramide, 4-(alpha-(p-chlorophenyl)-5-fluoro-2-hydroxybenzylideneamino)-
38. Progabide [who-dd]
39. Unii-112e50torv
40. Schembl35328
41. Schembl35329
42. Schembl340485
43. Schembl341677
44. Chembl287631
45. Chembl4796538
46. Dtxsid00878140
47. Chebi:135422
48. Hy-a0173
49. Zinc13519914
50. Zinc18153101
51. Akos016013958
52. Db00837
53. Cs-0017513
54. Ft-0674038
55. D05621
56. 666p200
57. A833914
58. Q426524
59. 4-((.alpha.-(p-chlorophenyl)-5-fluorosalicylidene)amino)butyramide
60. 4-[(4-chlorophenyl) (5-fluoro-2-hydroxy-phenyl)-methylene]amino Butanamide
61. 4-[[(4-chlorophenyl)-(5-fluoro-2-hydroxyphenyl)methylidene]amino]butanamide
62. 4-[[(4-chlorophenyl)( 5-fluoro-2-hydroxyphenyl)-methylene]amino ]butanamide
63. 4-[[(z)-(4-chlorophenyl)-(3-fluoro-6-oxo-cyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide;progabide
64. 4-{[(4-chlorophenyl)[(1e)-3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene]methyl]amino}butanamide
| Molecular Weight | 334.8 g/mol |
|---|---|
| Molecular Formula | C17H16ClFN2O2 |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 6 |
| Exact Mass | 334.0884336 g/mol |
| Monoisotopic Mass | 334.0884336 g/mol |
| Topological Polar Surface Area | 75.7 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 425 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Indicated for the treatment of epilepsy.
Progabide, a fatty acid derivative, is a GABA receptor agonist used to treat the symptoms of epilepsy.
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
Antidepressive Agents
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)
GABA Agonists
Endogenous compounds and drugs that bind to and activate GAMMA-AMINOBUTYRIC ACID receptors (RECEPTORS, GABA). (See all compounds classified as GABA Agonists.)
Antiparkinson Agents
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AG - Fatty acid derivatives
N03AG05 - Progabide
Absorption
Well absorbed with a bioavailability of 60%
Hepatic
4 hours
Progabide binds to both GABAA and GABAB receptors located on the terminals of primary afferent fibers. Binding to GABAA results in an increased affinity of the GABA receptor for the amino acid, an augmented flux of chloride ions across the terminal membrane, and an increase in the amount of presynaptic inhibition. Activation of the GABAB receptors retards the influx of calcium ions into the terminals, thereby reducing the evoked release of excitatory amino acids and possibly other transmitters.
ABOUT THIS PAGE
64
PharmaCompass offers a list of Progabide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Progabide manufacturer or Progabide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Progabide manufacturer or Progabide supplier.
PharmaCompass also assists you with knowing the Progabide API Price utilized in the formulation of products. Progabide API Price is not always fixed or binding as the Progabide Price is obtained through a variety of data sources. The Progabide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Progabide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Progabide, including repackagers and relabelers. The FDA regulates Progabide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Progabide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Progabide supplier is an individual or a company that provides Progabide active pharmaceutical ingredient (API) or Progabide finished formulations upon request. The Progabide suppliers may include Progabide API manufacturers, exporters, distributors and traders.
Progabide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Progabide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Progabide GMP manufacturer or Progabide GMP API supplier for your needs.
A Progabide CoA (Certificate of Analysis) is a formal document that attests to Progabide's compliance with Progabide specifications and serves as a tool for batch-level quality control.
Progabide CoA mostly includes findings from lab analyses of a specific batch. For each Progabide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Progabide may be tested according to a variety of international standards, such as European Pharmacopoeia (Progabide EP), Progabide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Progabide USP).
